Golimumab for treating moderately to severely active ulcerative colitis in people aged 2 to 17 years [TSID11959]

  • Topic selection

NIHRIO BN - 26526-Golimumab-for-Ulcerative-Colitis-V1.0-NOV2023-NON-CONF.pdf (nihr.ac.uk)